Granted Patent
B2
US 12,685,743 · App. 17/038,813 · Granted Jul 21, 2026
Methods and compositions for treating and diagnosing pancreatic cancers
Inventors:
George Miller (Englewood, NJ); Berk Aykut (Brooklyn, NY); Deepak Saxena (New York, NY); Smruti Pushalkar (New York, NY)
Assignee:
NEW YORK UNIVERSITY
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The application relates to methods based on modulating pancreatic and/or gastrointestinal microbiota and related antifungal compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.
Claims (7)
1 . A method for treating pancreatic ductal adenocarcinoma in a subject in need thereof, said method comprising administering to the subject an effective amount of an antifungal compound or composition, wherein the antifungal compound or composition inhibits growth of one or more strains of fungi from the species Malassezia globosa in the pancreatic and/or gastrointestinal microbiota of the subject, further comprising determining the level of at least one strain of fungi from the species Malassezia globosa in the pancreatic and/or gastrointestinal microbiota of the subject, wherein the antifungal compound or composition comprises amphotericin B or fluconazole.
2 . The method of claim 1 , wherein the subject has a functional mannose-binding lectin (MBL)-C3 convertase complement axis.
3 . The method of claim 1 , wherein the subject is human.
4 . The method of claim 1 , further comprising comparing the level of the at least one strain of fungi from the species Malassezia globosa in the pancreatic and/or gastrointestinal microbiota of the subject to the level of the same fungi in a control pancreatic and/or gastrointestinal microbiota.
5 . The method of claim 1 , wherein the subject displays an increase in at least one strain of fungi from the species Malassezia globosa in the pancreatic microbiota as compared to a control pancreatic microbiota.
6 . The method of claim 1 , wherein the subject displays an increase in at least one strain of fungi from the species Malassezia globosa in the gastrointestinal microbiota as compared to a control gastrointestinal microbiota.
7 . The method of claim 1 , wherein the antifungal compound is administered orally or intravenously from about 0.05 mg/ml to about 10 mg/ml per day.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 18, 2021
From: MILLER, GEORGE; AYKUT, BERK; SAXENA, DEEPAK; PUSHALKAR, SMRUTI
To: NEW YORK UNIVERSITY
Reel/Frame 055638/0787 →
Continuity (2)
Provisional Application
62909037
· Oct 1, 2019
Related Publication
20210260092A1
· Aug 26, 2021
References Cited (83)
US 20140378531A1
· Miller et al.
· 2014
[cited by applicant]
US 20160120915A1
· Blaser et al.
· 2016
[cited by applicant]
US 20210213073A1
· Zeng
· 2021
[cited by applicant]
US 20210260092A1
· Miller
· 2021
[cited by applicant]
US 20210315947A1
· Lynch
· 2021
[cited by applicant]
US 20210353694A1
· Possemiers
· 2021
[cited by applicant]
WO WO2006089406A1
· 2006
[cited by examiner]
WO 2015075688A1
· 2015
[cited by applicant]
WO 2016172657
· 2016
[cited by applicant]
WO 2018145082
· 2018
[cited by applicant]
WO 2020243705A1
· 2020
[cited by applicant]
WO 2020243731
· 2020
[cited by applicant]
Luo et al. (Pancreas vol. 48 No. 6, pp. 817-822, Jul. 2019).
[cited by examiner]
Chiorean et al. (Drug Design, Development and Therapy, vol. 5 No. 9, pp. 3529-3545, 2016).
[cited by examiner]
Akshintala, V. et al., “The Gut Microbiome in Pancreatic Disease” Clinical Gastroenterology and Hepatology (2019) Abstract, vol. 17, No. 2, 2 pages total.
[cited by applicant]
Chen, S-M. et al., “The Synergistic Tumor Growth-Inhibitory Effect of Probiotic Lactobacillus on Transgenic Mouse Model of Pancreatic Cancer Treated with Gemcitabine” Scientific Reports (2020) vol. 10, No. 20319, 12 pag…
[cited by applicant]
Gopalakrishnan, V. et al., “Intervention Strategies for Microbial Terapeutics in Cancer Immunotherapy” Immuno-Oncology Technology (2020) vol. 6, Issue C. pp. 9-17.
[cited by applicant]
Highlander, S.K. et al., “Gastrointestinal Microbiome Changes in Stage IV Pancreatic Cancer Patients Treated with Pembrolizumab With or Without Paricalcitol on the Stand Up to Cancer (SU2C) Pancreas Catalyst Trial” Amer…
[cited by applicant]
Thomas, R. M. et al., “Microbiota in Pancreatic Health and Disease: The Next Frontier in Microbiome Research” Castroentrology & Hepatology (2020) vol. 17, pp. 53-64.
[cited by applicant]
Zhou, W. et al., “The Fecal Microbiota of Patients with Pancreatic Ductal Adenocarcinoma and Autoimmune Pancreatitis Characterized by Metagenomic Sequencing” Journal of Translational Medicine (2021) vol. 19, No. 215, 12…
[cited by applicant]
Afshar-Kharghan, V. The role of the complement system in cancer. J. Clin. Invest. 127, 780-789 (2017).
[cited by applicant]
Brown, J.H., Whitham, T.G., Morgan Ernest, S.K. & Gehring, C.A. Complex Species Interactions and the Dynamics of Ecological Systems: Long-Term Experiments. Science 293, 643-650 (2001).
[cited by applicant]
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335-336 (2010).
[cited by applicant]
Caporaso, J.G., et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. The ISME Journal 6, 1621-1624 (2012).
[cited by applicant]
Cho, M. S. et al. Autocrine effects of tumor-derived complement. Cell Reports 6, 1085-1095 (2014).
[cited by applicant]
Communication (International Preliminary Report on Patentability) issued by the International Searching Authority in International Application No. PCT/US2018/017052 dated Aug. 6, 2019, 13 pages total.
[cited by applicant]
Communication (International Search Report) issued by the International Searching Authority in International Application No. PCT/US2018/017052 dated May 8, 2018, 4 pages total.
[cited by applicant]
Communication (Written Opinion) issued by the International Searching Authority in International Application No. PCT/US2018/017052 dated May 8, 2018, 12 pages total.
[cited by applicant]
Edgar, R.C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460-2461 (2010).
[cited by applicant]
Farrell, J.J., et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61, 582-588 (2012).
[cited by applicant]
Haas, B.J., et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Research 21, 494-504 (2011).
[cited by applicant]
Hamada, S. et al., “Differences in Gut Microbiota Profiles between Autoimmune Pancreatitis and Chronic Pancreatitis” Tohoku Journal of Experimental Medicine (2018) vol. 244, No. 2, pp. 113-117.
[cited by applicant]
Herlemann, D.P.R., et al. Transitions in bacterial communities along the 2000km salinity gradient of the Baltic Sea. ISME J 5, 1571-1579 (2011).
[cited by applicant]
Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
[cited by applicant]
Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
[cited by applicant]
Hruban. R. H. et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 25, 579-586 (2001).
[cited by applicant]
Ino, Y., et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. British journal of cancer 108, 914-923 (2013).
[cited by applicant]
Ishikawa, T. et al. Identification of distinct ligands for the C-type lectin receptors mincle and dectin-2 in the pathogenic fungus Malassezia. Cell Host Microbe 13, 477-488 (2013).
[cited by applicant]
Kamada, N., Seo, S.-U., Chen, G.Y. & Nunez, G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 13, 321-335 (2013).
[cited by applicant]
Klindworth, A., et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Research 41, e1-e1 (2013).
[cited by applicant]
Leal-Lopes, C. et al., “Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies” Hindawi Publishing Corporation (2015) vol. 2015m Article ID 284680, 20 pages total.
[cited by applicant]
Masella, A.P., Bartram, A.K., Truszkowski, J.M., Brown, D.G. & Neufeld, J.D. PANDAseq; paired-end assembler for Illumina sequences. BMC Bioinformatics 13, 31-31 (2012).
[cited by applicant]
Mi, H., Muruganujan, A., Casagrande, J.T. & Thomas, P.D. Large-scale gene function analysis with the PANTHER classification system. Nature protocols 8, 1551-1566 (2013).
[cited by applicant]
Michaud, D.S., Joshipura, K., Giovannucci, E. & Fuchs, C.S. A Prospective Study of Periodontal Disease and Pancreatic Cancer in US Male Health Professionals, Journal of the National Cancer Institute 99, 171-175 (2007).
[cited by applicant]
Mitsuhashi, K., et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget; vol. 6, No. 9 (2015).
[cited by applicant]
Navas-Molina, J.A., et al. Advancing our understanding of the human microbiome using QIIME. Methods in Enzymology 531, 371-444 (2013).
[cited by applicant]
Plottel, C.S. & Blaser, M.J. Microbiome and Malignancy. Cell host & microbe 10, 324-335 (2011).
[cited by applicant]
Price, M.N., Dehal, P.S. & Arkin, A.P. FastTree: Computing Large Minimum Evolution Trees with Profiles instead of a Distance Matrix. Molecular Biology and Evolution 26, 1641-1650 (2009).
[cited by applicant]
Pushalkar, S. et al., “The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression” Cancer Discovery (2018) vol. 8. No. 4, pp. 403-416.
[cited by applicant]
Pushalkar, S., et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiology 12, 144-144 (2012).
[cited by applicant]
Pushalkar, S., et al. Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw. In J Oral Sci 6, 219-226 (2014).
[cited by applicant]
Reikvam, D. H. et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS One 6, e17996 (2011).
[cited by applicant]
Rutkowski, M.R., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer cell 27, 27-40 (2015).
[cited by applicant]
Sam, Q. H., Chang, M. W. & Chai, L. Y. The fungal mycobiome and its interaction with gut bacteria in the host. Int. J. Mol. Sci. 18, 330 (2017).
[cited by applicant]
Schwabe, R.F. & Jobin, C. The microbiome and cancer. Nature reviews. Cancer 13, 800-812 (2013).
[cited by applicant]
Segata, N., et al. Metagenomic biomarker discovery and explanation. Genome Biology 12, R60-R60 (2011).
[cited by applicant]
Seifert, L. et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532, 245-249 (2016).
[cited by applicant]
Seifert. L., et al. Radiation Therapy Induces Macrophages to Suppress Immune Responses Against Pancreatic Tumors in Mice. Gastroenterology (2016).
[cited by applicant]
Skalski, J. H. et al. Expansion of commensal fungus Wallemia mellicola in the gastrointestinal mycobiota enhances the severity of allergic airway disease in mice. PLoS Pathog. 14, e1007260 (2018).
[cited by applicant]
Van Asbeck, et al., “Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells” BMC Microbiol. 8, 229 (2008).
[cited by applicant]
Walters, W. et al. Improved bacterial 16S rRNA gene (V4 and V4-5) and fungal internal transcribed spacer marker gene primers for microbial community surveys. mSystems 1, e00009-15 (2015).
[cited by applicant]
Zambirinis, C.P., et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. The Journal of Experimental Medicine 212, 2077-2094 (2015).
[cited by applicant]
Office Action issued Aug. 5, 2021 in connection with U.S. Appl. No. 16/484,080.
[cited by applicant]
Office Action issued Mar. 17, 2022 in connection with U.S. Appl. No. 16/484,080.
[cited by applicant]
Shah et al., “Trends in Food Science & Technology,” 102 (2020) 178-192. available online Jun. 23, 2020 (Year: 2020).
[cited by applicant]
Routy et al., European Urology 74 (2018) 521-526 (Year: 2018).
[cited by applicant]
Routy et al., Nature Reviews, Clinical Oncology. Jun. 2018, 15:385-396. published online: Apr. 10, 2018 (Year: 2018).
[cited by applicant]
Messaoudene et al., Cancer Research (Aug. 2020) vol. 80, No. 16 Suppl. Abstract No. 5730 (Year: 2020).
[cited by applicant]
Office Action issued Nov. 1, 2022 in connection with U.S. Appl. No. 16/484,080.
[cited by applicant]
Janda et al., “16S rRNA Gene Sequencing for Bacterial Identification in the Diagnostic Laboratory: Pluses, Perils, and Pitfalls”, Sep. 2007, Journal of Clinical Microbiology, vol. 45, No. 9, p. 2761-2764, (Year: 2007).
[cited by applicant]
Jiang et al., “Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy”, Aug. 2016, Nature Medicine, vol. 22, No. 8, p. 851-860. (Year: 2016).
[cited by applicant]
Dingemanse et al., “Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice”, 2015, Carcinogenesis, vol. 36, No. 11, p. 1388-1396 (Year: 2015).
[cited by applicant]
Aykut et al., “The Fungal Mycobiome Promotes Pancreatic Oncogenesis via Activation of MBL” Nature 2019 vol. 574:264-267.
[cited by applicant]